Prostaglandin D synthetase [(5Z,13E 
The enzyme showed full activity with 1 mM glutathione, 1 mM 2-mercaptoethanol, or 0.5 mM dithiothreitol and was almost completely inhibited by 1 mM 1-chloro-2,4-dinitrobenzene. The Km value for prostaglandin H2 was about 20 pM. These catalytic properties are the same as those of rat brain prostaglandin D synthetase but different from those of rat spleen prostaglandin D synthetase. The activity decreased to <20% of its initial level after incubation with excess amounts of a polyclonal or a monoclonal antibody against the brain enzyme, but the activity remained unchanged with a polyclonal antibody against the spleen enzyme, indicating that the brain-type enzyme synthesizes prostaglandin D2 in the cochlea. When cryosections of 5-week-old (adult) rat cochleas were stained by an immunoperoxidase method with antibodies against the brain enzyme, the immunoreactivity was found in inner and outer hair cells, Claudius' cells, Deiters' cells, marginal cells, basal cells, and cells ofReissner's membrane. In 8-day-old rats, the immunoreactivity was found in all of these cell types except hair cells. The immunoreactivity in hair cells was found in only one specimen from 9-day-old animals, and no immunoreactivity was found in spiral ganglion cells at any of the ages exanined. These rmdings indicate that prostaglandin D2 is produced by the brain-type synthetase in the indicated types of cochlear cells.
Prostaglandin (PG) D2 is a major PG in the central nervous system (1, 2) . Its injection into the brain ventricle causes hypothermia (3) and sleep (4, 5) . It also shows several peripheral actions, such as bronchoconstriction (6, 7) , vasoconstriction and/or vasodilation (7, 8) , and inhibition of platelet aggregation (9) (10) (11) . PGD2 is produced by isomerization of PGH2 by the catalytic action of POD synthetase (5Z,13E)-(15S)-9a,lla-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase (EC 5.3.99.2). Two different types of the enzyme have been purified separately from brain (12) and spleen (13, 14) . Analysis of the purified enzymes shows that they are similar in some aspects but in other aspects differ biochemically and immunochemically (14) . For example, the spleen enzyme requires glutathione (GSH) to exert its full activity and is an anionic form of GSH S-alkyltransferase (RX:glutathione R-transferase, EC 2.5.1.18), whereas the brain enzyme does not specifically require GSH for its activity and also is active with other sulfhydryl compounds such as 2-mercaptoethanol and dithiothreitol. In the Ouchterlony immunodiffusion test, antibody raised against the brain PGD synthetase immunoprecipitates this enzyme but not spleen PGD synthetase, whereas the antibody raised against the spleen enzyme immunoprecipitates the spleen enzyme but not the brain enzyme (14) .
Using polyclonal and monoclonal antibodies against the PGD synthetase purified from rat brains (12), we have previously localized the enzyme immunocytochemically in the brain (15) . Interestingly, the distribution of immunoreactivity depends on the developmental stage of animals; it appeared in neurons of 2-week-old rats but mainly in oligodendrocytes in 8-week-old rats (15) . As for tissue specificity, we found the immunoreactivity against the brain PGD synthetase only in the central nervous system, including the brain, spinal cord, and retina, but not in other tissues.
Other laboratories have found PGE2, PGF2, and 6-ketoPGFia in the perilymph of the cochlea (16) and have demonstrated the synthesis of PGE2, PGF2a, 6-keto-PGF1,^, and thromboxane B2 by the lateral wall of the cochlear duct in vitro (17) . Recently, we have found in vitro synthesis of PGD2, as well as of PGE2, PGF2,, and 6-keto-PGFia, by the lateral wall of the cochlea and by the combined tissues of the organ of Corti and modiolus (R. Kawata, 0. S. Mizukoshi, M.T., and Y.U., unpublished data). In this paper we show biochemically and immunologically that the brain-type PGD synthetase was involved in the formation of PGD2 in the cochlea and also present the cellular localization of the enzyme by immunoperoxidase staining of the cochlea with antibody against this enzyme. MATERIALS AND METHODS Antibody. A polyclonal antiserum against rat brain PGD synthetase was elicited in a rabbit by using the enzyme purified to apparent homogeneity from a crude extract of the brain of Wistar rats; the IgG fraction of this antiserum was separated as previously described (12) . A monoclonal antibody (IgGl) against the brain PGD synthetase was obtained from BALB/c mice immunized with the highly purified enzyme by the cell-fusion technique with myeloma (NS-1) cells (18), as described fully elsewhere (15) . A polyclonal antiserum against rat spleen PGD synthetase was produced in a rabbit by using the apparently homogeneous enzyme preparation purified from a crude extract of rat spleen, and its IgG fraction was separated as described elsewhere (14) .
Enzyme Assay. Five-week-old Wistar rats were deeply anesthetized with pentobarbital and perfused through the heart with 150 ml of Ringer's solution. Membranous cochleas were dissected in Ringer's solution under a stereomicro- 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. a sonicator (model W-255, Heat Systems-Ultrasonics). The homogenate was centrifuged at 100,000 x g for 1 hr, and the supernatant was used for the assay of PGD synthetase activity. The enzyme reaction occurred in 50 gl of 0.1 M Tris HCI, pH 8.0, containing 1 mM GSH at 250C for 1 min after addition of [1-14C] PGH2 (final concentration, 40 gM), unless otherwise stated. Termination of reaction, extraction, and quantification of products were done as described previously (12, 14) . For an inhibition test of the PGD synthetase activity, 1-chloro-2,4-dinitrobenzene was dissolved in ethanol and dried in assay tubes under N2 gas. The assay mixture was added to the tube, and then the PGD synthetase activity was determined. For immunoabsorption analyses, 50 gl of the supernatant (100,000 x g) of the cochlear homogenate was incubated at 40C overnight with excess (50 ,ug) polyclonal or monoclonal anti-(rat brain PGD synthetase) IgGs or excess polyclonal anti-(rat spleen PGD synthetase) IgG; when the monoclonal antibody was included, the mixture was further incubated with excess (1 mg) anti-mouse IgG antibody (Cappel Laboratories, Cochranville, PA) at room temperature for 30 min. Incubation for the control was done with an IgG fraction obtained from nonimmunized rabbits or mice. After incubation with the antibody, the reaction mixture was centrifuged at 10,000 x g for 10 min, and the resulting supernatant was recovered for the determination of PGD synthetase activity. Protein concentration was determined by the method of Lowry et al. (19) using bovine serum albumin as standard.
Immunocytochemistry. Wistar rats ofboth sexes (at least 10 animals of each age) were used 8 or 9 days and 5 weeks after birth. Under pentobarbital anesthesia, rats were perfused through the heart with Ringer's solution followed with a fixative (2% paraformaldehyde/1% picric acid/0.1 M sodium phosphate buffer, pH 7.4) of 1.5 vol ofbody weight. Cochleas were dissected and immersed in an acidic fixative (2% paraformaldehyde/1% picric acid/0.1 M sodium acetate buffer, pH 4.5) for 5-7 days. Next, the tissue was transferred to 6% sucrose in PBS for 2 days, and then 10-,m cryosections were cut and affixed to glass slides. After blocking with 10o normal goat serum at 4°C for 1 hr, the sections were incubated with the antibody at 4°C overnight. The serum and the antibody were dissolved in PBS containing 0.3% Triton X-100. Concentrations of the antibodies used were as follows: polyclonal anti-(rat brain PGD synthetase) IgG, 7 ,g/ml; monoclonal anti-(rat brain PGD synthetase) IgG1, 10 ,ug/ml; and polyclonal anti-(rat spleen PGD synthetase) IgG, 10 ,ug/ml. The sections were further processed for immunoperoxidase staining with a Vectastain ABC kit (Vector Laboratories, Burlingame, CA) by the method of Hsu et al. (20) and visualized with diaminobenzidine HCl as a chromogen. Immunohistochemical control was done by replacing the first antibody with the IgG fraction obtained from nonimmunized rabbits or mice, and the antibodies were preabsorbed with excess amounts of the purified enzymes. RESULTS PGD Synthetase Activity in the Cochlea. When the cochlear homogenate of adult rats was incubated with 40 ,uM PGH2 in the presence of 1 mM GSH, dose-dependent conversion of PGH2 to PGD2 was seen. However, no enzymic conversion of PGH2 to PGE2 or PGF2a was found during the incubation, and thus PGD2 was the major PG formed from PGH2 in the cochlear homogenate. The PGD synthetase activity was almost completely recovered in the 100,000 x g supernatant fraction (Fig. 1) , and the specific activity (14.0 ± 1.0 nmol/min per mg of protein, mean ± SEM of three determinations) was 6-and 7-fold higher than those ofthe brain and spinal cord, respectively (21) . Full were nonenzymically degraded to PGE2 and PGF2,,, respectively, no enzymic formation of these PGs was detected during incubation of the cochlear supernatant. The protein concentration of the supernatant was 1.0 mg/ml.
2-mercaptoethanol and 0.5 mM dithiothreitol substituted for 1 mM GSH. The synthetase activity was almost completely inhibited by 1 mM 1-chloro-2,4-dinitrobenzene even in the presence of those sulfhydryl compounds. The Km value for PGH2 ofthe synthetase activity was calculated to be -20 tLM.
These catalytic properties are quite similar to those of rat brain PGD synthetase and clearly different from those of rat spleen PGD synthetase (14) . Furthermore, after incubation with excess amounts of the polyclonal or monoclonal antibodies against rat brain PGD synthetase, the synthetase activity in the cochlear homogenate decreased to 15% or 23%, respectively, of the initial activity before incubation. On the other hand, the activity remained unchanged after incubation with the antibody against rat spleen PGD synthetase or with IgGs from nonimmunized animals. Therefore, adult rat cochlea appears to contain PGD synthetase of brain-type but not of spleen-type.
Immunocytochemistry of PGD Synthetase in the Cochlea. When the cochlea was stained for immunoperoxidase, specific immunoreactivity was found with the antibodies against brain PGD synthetase but not with the antibody against spleen PGD synthetase at any ages we examined. Localization of immunoreactivity in the cochlea visualized by the polyclonal and monoclonal IgGs against brain PGD synthetase was essentially the same. The use of IgGs from nonimmunized animals or the preabsorbed IgGs resulted in no immunoreactivity. Distribution of immunoreactivity of the brain-type PGD synthetase seen in the cochlea of premature and mature rats was as follows:
(i) Organ of Corti. Immunoreactivity was not found in hair cells of 8-day-old premature rats. Only in one cochlea of the 9-day-old premature rats did inner hair cells show an immunoreactivity in their cytoplasm (Fig. 2a) . In contrast, the immunoreactivity was found in the cytoplasm of both outer and inner hair cells in 5-week-old mature rats (Fig. 2b) . In both premature and mature rats, Hensen's cells, especially those located most externally, and Claudius' cells were frequently immunoreactive (Fig. 2 a and c) . were less frequently reactive (Fig. 2d) . No immunoreactivity was found in the spiral ganglion cells.
(ii) Lateral wall and Reissner's membrane. In both premature and mature rats, the cytoplasm of marginal cells and of basal cells of the vascular stria was immunoreactive. In the marginal cells, the immunoreactivity was more intense at the apical portion of the cytoplasm. Immunoreactivity was also found in the cytoplasm of cells of Reissner's membrane ( Fig.   2 e and] ).
DISCUSSION
The results of the present study show that the cochlea of adult rats is enriched in the brain-type PGD synthetase activity, which has a specific activity (14.0 nmol/min per mg of protein) 6-to 7-fold higher than that in the central nervous system (brain, 2.5 nmol/min per mg of protein; spinal cord, 2.0 nmol/min per mg of protein) (21) immunoreactivity in other receptor cells such as vestibular hair cells, olfactory cells, and rods and cones using our antibodies against rat brain PGD synthetase. Thus far, however, the immunoreactivity has been found only in vestibular hair cells (M.T. and Y.U., unpublished data). The presence of brain-type PGD synthetase, therefore, is not a universal property of receptor cells in general but seems to be specific to inner-ear receptor cells. The functional significance of PGD synthetase, or of PGD2, in the cochlear hair cells can presently be only a matter of speculation. This study indicates that the PGD synthetase-like immunoreactivity in the hair cells first appears r9 days after birth; in comparison, others have found that cochlear microphonics first occur 8 or 9 days after birth in rats (22, 23) . The coincidence ofthese two events suggests that PGD2 may be involved in biologically important phenomena in the cochlear hair cells.
It is also interesting to see the PGD synthetase-like immunoreactivity in marginal cells of the vascular stria, which have a role in the regulation of the composition of the cochlear endolymph (24) . Presence of such immunoreactivity in the stria at the age of 8 or 9 days after birth may reflect the maturation of those cells because the ionic composition of cochlear endolymph at these ages has reportedly already reached a nearly adult level in rats (25) . The finding of immunoreactivity in basal cells of the stria was unexpected because these cells are mesodermal (26) , and mesodermal cells have not been found to contain brain-type PGD synthetase.
To summarize, the finding of PGD synthetase-like immunoreactivity in a wide variety of rat cochlear cells indicates that PGD2 is probably a biologically important cochlear PG and is involved in various functions in the mammalian cochlea.
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